Trial Profile

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pitavastatin (Primary)
Indications Cardiovascular disorders
Focus Therapeutic Use
Acronyms REPRIEVE; REPRIEVE; REPRIEVE EU

Most Recent Events

09 Mar 2025 According to a ACTG media release, data from this trial were shared as the late breaking poster presentation at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.
09 Mar 2025 Results presented in the ACTG media release.
23 Jul 2024 According to an AIDS Clinical Trials Group media release, the trial is led by Pamela S. Douglas, M.D,Ribaudo, Ph.D. (Lead Statistician) and Michael Lu, M.D., M.P.H. (Protocol Chair, Mechanistic Substudy of REPRIEVE), who led the Data Coordinating Center.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com